The a-synuclein protein, encoded by SNCA, has a key role in the pathogenesis of Parkinson's disease and other synucleinopathies. Although usually sporadic, Parkinson's disease can result from inherited copy number variants in SNCA and other genes. We have hypothesized a role of somatic SNCA mutations, leading to mosaicism, in sporadic synucleinopathies. The evidence for mosaicism in healthy and diseased brain is increasing rapidly, with somatic copy number gains of APP reported in Alzheimer's brain. Here we demonstrate somatic SNCA copy number gains in synucleinopathies (Parkinson's disease and multiple system atrophy), focusing on substantia nigra. We selected sporadic cases with relatively young onset or short disease duration, and first excluded high level copy number variant mosaicism by DNA analysis using digital PCR for SNCA, and/or customized array comparative genomic hybridization. To detect low level SNCA copy number variant mosaicism, we used fluorescent in situ hybridization with oligonucleotide custom-designed probes for SNCA, validated on brain and fibroblasts with known copy number variants. We determined SNCA copy number in nigral dopaminergic neurons and other cells in frozen nigra sections from 40 cases with Parkinson's disease and five with multiple system atrophy, and 25 controls, in a blinded fashion. Parkinson's disease cases were significantly more likely than controls to have any SNCA gains in dopaminergic neurons (P = 0.0036), and overall (P = 0.0052). The average proportion of dopaminergic neurons with gains in each nigra was significantly higher in Parkinson's disease than controls (0.78% versus 0.45%; P = 0.017). There was a negative correlation between the proportion of dopaminergic neurons with gains and onset age in Parkinson's disease (P = 0.013), but not with disease duration, or age of death in cases or controls. Cases with tremor at onset were less likely to have gains (P = 0.035). All multiple system atrophy cases had gains, and the highest levels in dopaminergic neurons were in two of these cases (2.76%, 2.48%). We performed selective validation with different probes after dye swapping. All three control probes used showed minimal or no gains (40.1% in dopaminergic neurons). We also found occasional SNCA gains in frontal neurons of cases with Parkinson's disease, and the putamen of one multiple system atrophy case. We present evidence of somatic SNCA gains in brain, more commonly in nigral dopaminergic neurons of Parkinson's disease than controls, negatively correlated with onset age, and possibly commonest in some multiple system atrophy cases. Somatic SNCA gains may be a risk factor for sporadic synucleinopathies, or a result of the disease process.
Introduction
Parkinson's disease is usually sporadic, although it can result from inherited mutations, including copy number variants, in SNCA and other genes (Mullin and Schapira, 2015; Petrucci et al., 2016) . The -synuclein protein appears crucial to the pathogenesis of sporadic Parkinson's disease, yet SNCA mutations are very rare in DNA from peripheral blood leucocytes. Mosaicism, the presence in an organism of cells with genetic differences due to post-zygotic somatic mutations, is increasingly recognized (Macosko and McCarroll, 2012; Lupski, 2013) . Somatic mutations may affect the risk of sporadic diseases (Forsberg et al., 2013) , and neurodegeneration (LeijaSalazar et al., 2018) . Inherited (constitutional) copy number variants contribute to variation between individuals (Zarrei et al., 2015) , while somatic gains or losses lead to copy number mosaicism. This appears widespread (Abyzov et al., 2012; O'Huallachain et al., 2012) , established early in development (Mkrtchyan et al., 2010) , and has been repeatedly shown in single frontal neurons from healthy individuals (Gole et al., 2013; McConnell et al., 2013; Cai et al., 2014) . Aberrant neuronal DNA synthesis may also arise as a result of neurodegeneration (Frade et al., 2015) . Brain mosaicism also exists for point mutations (Lodato et al., 2015; Hazen et al., 2016) , aneuploidy (Rehen et al., 2005; Arendt et al., 2010; Knouse et al., 2014) , and retrotransposon insertions (Baillie et al., 2011; Thomas et al., 2012; Evrony et al., 2015) . In Alzheimer's disease somatic APP gains occur preferentially in frontal neurons (Bushman et al., 2015) , and somatic point mutations have been reported (Beck et al., 2004; Frigerio et al., 2015) .
Heritability for Parkinson's disease is 535% (Wirdefeldt et al., 2011; Keller et al., 2012) , and for multiple system atrophy (MSA) 510% (Federoff et al., 2016) . There is therefore a clear need to search for additional aetiological factors. We have hypothesized a role of somatic SNCA mutations in sporadic Parkinson's disease (Proukakis et al., 2013) . Somatic SNCA gains in the neuroectodermal lineage could lead to disease if over a threshold in a particular region or cell type, or increase the risk synergistically with other factors (inherited risk alleles, epigenetic changes, environmental influences), and could act as initiators or facilitators of pathology spread. Broad spatial dispersal of early developmental mutations could explain Parkinson's disease widespread pathology (Proukakis et al., 2013) . MSA, a predominantly glial synucleinopathy, has significant neuronal pathology (Cykowski et al., 2015) , and certain SNCA inherited mutations also lead to MSA phenotypes (Fujishiro et al., 2013; Kiely et al., 2013) . We found no coding SNCA point mutations in 4500 Parkinson's disease/dementia with Lewy bodies brains in mostly cerebellar DNA, with a 5-10% mutation level detection threshold . Inherited SNCA copy number gains (duplications, triplications), while rare, are more frequent than inherited point mutations, with severity and onset age related to gene dosage (Kasten and Klein, 2013) . SNCA is located within a chromosomal fragile site (Rozier et al., 2004) , where breaks may arise from DNA replication stress (Arlt et al., 2009) . DNA rearrangements have long been suspected in neurogenesis (Chun and Schatz, 1999) , and DNA breaks have been demonstrated recently (Schwer et al., 2016; Wei et al., 2016) .
In this work, we present evidence of somatic SNCA gains in nigral dopaminergic neurons from synucleinopathies, where they are more common than in controls, and negatively correlated with the age of onset in Parkinson's disease. We detect some evidence of gains in other cell types and brain regions, and validate our results with different probes. Somatic SNCA gains may be a risk factor for sporadic synucleinopathies, or a result of the disease process.
Methods and materials Patients
Material from fresh frozen brain of patients with Parkinson's disease and MSA, and controls, was provided by the Parkinson's UK Tissue Bank and the Queen Square Brain Bank. The latter also provided limited fixed sections. Fixed sections of a brain carrying a heterozygous SNCA duplication were provided by the South West Dementia Brain Bank. Donors had given informed written consent. Study of brains from the research tissue banks is approved by the UK National Research Ethics Service (07/MRE09/ 72), and we had additional approval by the National Research Ethics Service London -Hampstead (10/H0729/ 21). In total, 41 patients with Parkinson's disease, five patients with MSA, and 30 control subjects were studied to some extent, but because of limited material available, not all experiments were performed on each. Demographic data, and details of experiments and key results, are in Supplementary Table 1. Patients were selected for either (i) relatively short disease duration (410 years), where vulnerable neurons with somatic mutations may not have all died; or (ii) relatively young onset (460 years), as these may have higher mosaicism level/mutation load (Frank, 2010; Proukakis et al., 2013) ; only eight fulfilled both these criteria. All controls had had -synuclein immunohistochemistry except for one (Subject C13). They had an older age at death, as aged individuals with negative -synuclein immunohistochemistry were considered more suitable, since younger 'controls' could have developed pathology later in life. We excluded cases and controls with a first degree relative with Parkinson's disease. All cases had been screened for the LRRK2 G2019S mutation. One young onset case (Case PD3; onset age 44), who underwent genetic testing in life, had a very rare heterozygous PARK2 coding variant of uncertain significance (c.1195G 4 A; p.Glu399Lys; frequency 0.0015% in Europeans in Exome Aggregation Consortium http://exac.broadinstitute.org, accessed 6/10/ 2017). All brain bank reports were available, and review of pathology sections where required was performed by a senior neuropathologist (J.L.H. for Queen Square, and S.G. for Parkinson's UK). Staging was performed according to the McKeith (McKeith et al., 2005) and Braak (Braak et al., 2003) criteria.
DNA analysis by array comparative genomic hybridization and droplet digital PCR DNA was extracted using Blood and Tissue DNeasy Õ kit (Qiagen), or phenol-chloroform, as described (Nacheva et al., 2017) . Array-comparative genomic hybridization (CGH) was performed using our custom 8 Â 60 k array (Agilent), densely tiled for relevant genes (SNCA, PARK2, GBA, PARK7, PINK1, LRRK2, ATP13A2, VPS35, NURR1, POLG, PANK2, PLA2G6, EIF4G1, MAPT) (Nacheva et al., 2017) . Analysis was performed with Agilent Genomic Workbench 7.0 using the ADM2 algorithm (threshold 6, five consecutive probes and 10 kb size needed for a call). The 'fuzzy zero' long range correction was used, because removing it may help detect mosaicism (Valli et al., 2011) , but also allows artefacts due to GCrelated DNA isolation bias to be called (Nacheva et al., 2017) . Data were mapped to hg19. We only considered samples with adequate quality hybridization (derivative log ratio spread 50.3 as recommended by Agilent).
Droplet digital PCR was performed on the Bio-Rad QX200 as described (Nacheva et al., 2017) . The SNCA probe was dHsaCP1000476 (FAM-labelled), and HEXlabelled RPP30 (dHsaCP1000485) was used as reference. Reactions were performed in two or more replicates. In the case of samples extracted with spin columns, which may be particularly prone to isolation bias (Nacheva et al., 2017) , any samples with copy number 42.2 or 51.8 were reanalysed after phenol-chloroform extraction; the latter result is provided. 'Artificial mosaics' for SNCA copy number were prepared by mixing DNA from triplication fibroblasts, or blood from a duplication patient , with control DNA.
FISH
We used labelled oligonucleotide 'SureFISH' probes (Agilent Technologies) (Fig. 1A) . Probes for SNCA were custom-designed, aiming to keep them as small as possible to minimize the chance of adjacent signals merging, which may lead to false negatives (Bushman et al., 2015) . Commercially available control probes were chosen, initially on the same chromosome, but far from the fragile site around SNCA. A $50 kb red probe was used initially, and a $100 kb green probe for further validation. Dualcolour (red/green) fluorescent in situ hybridization (FISH) was performed, with nuclei stained blue using DAPI. Whole chromosome paint for chromosome 4 (Kreatech) was used in the same protocol, by replacing the reference probe with whole chromosome paint.
After initial optimization (Supplementary material, Note 1), we used 10 mm sections from snap-frozen brain tissue unless specified. Slides were left at room temperature for 30 min and then incubated for 30 min at 37 C in pepsin (0.05% in 0.01% HCl). To inactivate pepsin, slides were transferred to 0.01 M MgCl 2 in phosphate-buffered saline (PBS) for 5 min, and then to a MgCl 2 solution with 3% formaldehyde for 10 min. They were then washed twice for 5 min in PBS and dehydrated in an ethanol series. After airdrying, they were denatured in 70% formamide solution at 73 C for exactly 2 min, and then dehydrated again in an ethanol series. The probes were mixed (3 ml hybridization buffer, 1 ml sterile water, 1 ml of each of the SNCA and control probes) and denatured at 73 C for 5 min. Five microlitres of the denatured mix was applied to the denatured and air-dried tissue on the slide, covered with a coverslip and incubated for 72 h at 37 C. After hybridization, slides were washed in Agilent SureFISH buffers 1 (2 min, 73 C) and 2 (1 min, room temperature), incubated for 20 min in 0.1% Sudan Black B (in 70% ethanol) to reduce autofluorescence (Oliveira et al., 2010) , washed three times for 5 min in PBS, and DAPI was applied. Fixed slides first underwent deparaffinization. They were incubated overnight at 65 C, and then immersed in xylene three times, for 10 min, at room temperature. They were then dehydrated twice, for 5 min, in absolute ethanol, treated with 0.1 M citric acid solution (pH 6) for antigen retrieval using microwave heating for 20 min, and then washed twice, for 5 min, with dH 2 O.
To prepare fibroblasts for FISH, cells were incubated overnight with colcemid (100 ml per 5 ml of cells, 10 6 cells per ml). The next day cells were harvested in 0.075 M warm KCl for 15 min at room temperature and then fixed in Carnoy's fixative (3:1 methanol: acetic acid).
Fresh slides were made and FISH performed using the protocol for frozen slides.
Slides were visualized on a BX61 automated epifluorescence microscope (Olympus) equipped with an ORCAII-ER CCD camera (Hamamatsu Photonics UK Ltd.) and images captured using SmartCapture 3 software (DSUK Limited, Cambridge, UK). To ensure no bias, all copy numbers were determined on the microscope, by the same experienced observer (K.M.), blinded to disease status, and demographics (except for certain later experiments which were not blinded, as specified in the results). In substantia nigra, we detected dopaminergic neurons by their neuromelanin content, a reliable marker that is probably more robust than tyrosine hydroxylase, which can be lost in Parkinson's disease (Kordower et al., 2013) . It was also used to identify dopaminergic neurons in a recent RNA sequencing study (Nichterwitz et al., 2016) . Cells were therefore classified as neuromelanin-positive, corresponding to dopaminergic neurons, and neuromelanin-negative, which likely were mostly glial, although we cannot exclude other neuronal cell types. Cells of each type were counted in a systematic unbiased way ( Supplementary Fig. 1 ), aiming for 150 neuromelanin-positive and 300 neuromelanin-negative cells. Substantia nigra samples were scored as positive or negative for each cell type, if they had any cells with gains. Additionally, for each section, the copy number of SNCA and the reference was individually recorded for each nucleus. The key result was the proportion of nuclei of each type with a gain of SNCA and normal reference (and vice versa). We also calculated the numbers of cells with gains of both probes, or losses of any, the mean copy number of SNCA, and the total number of signals for each probe. These are discussed in the results section. Similar metrics were recorded for other brain regions analysed, but without neuromelanin scoring.
Immunohistochemistry
To detect SNCA copy numbers in frontal cortex, FISH using SNCA probe was combined with immunohistochemistry for NeuN, widely used for cortical neuronal identification (Westra et al., 2010 To detect a high level of copy number variant mosaicism, we first analysed brain DNA by array-CGH customized for Parkinson's genes including SNCA and PARK2 (Nacheva et al., 2017) , and droplet digital PCR for SNCA, which is more suitable than quantitative PCR for copy number determination, including mosaicism (Kluwe, 2016) . To estimate the sensitivity of these assays for SNCA, we 'spiked' DNA samples with known SNCA copy number variants into control DNA at variable ratios, to create 'artificial mosaics' for gains. For array-CGH, the detection threshold was 30% heterozygous mosaicism (leading to a 15% increase in genomic material, equivalent to copy number 2.3) ( Supplementary Fig.  2 ). We analysed DNA from at least one region of 26 Parkinson's disease and 12 control brains, including nigra in most (Supplementary Tables 1 and 2 ). For SNCA digital PCR, copy number 2.2 appeared to be the detection threshold ( Supplementary Fig. 3A ). We used it to analyse DNA from the nigra of 36 Parkinson's disease, two MSA, and 11 controls (Supplementary Fig. 3B and Supplementary  Table 1 ). In total, 38 Parkinson's disease nigras were analysed with at least one of these methods, and 20 with both. We found no evidence of high level mosaicism.
FISH allows direct visualization of SNCA copy number
To detect any lower level gains, we first performed pilot FISH work using bacterial artificial chromosome probes, on unselected cell smears from substantia nigra. These suggested occasional gains, but did not allow definitive assessment (Supplementary material, Note 2). To improve on this, we used a customized SNCA 'SureFISH' probe, made of individual labelled oligonucleotides 120 basepairs each, tiling 50 kb of the SNCA locus (Fig. 1A) , emitting a red signal. These recently developed probes avoid repetitive sequences and other sources of error in bacterial artificial chromosomes, and provide excellent quality signals without noise (Sugita et al., 2017; Takeda et al., 2017) . We used the smallest size recommended, as larger probes might lead to nearby signals merging (Bushman et al., 2015) . We expected that a gain of SNCA could involve most of the $12 Mb fragile site around it (Fungtammasan et al., 2012) , as inherited copy number variants can be several megabases long (Ross et al., 2008; Kara et al., 2014) , but not extend beyond it. We therefore used catalogue green-labelled probes, located on chromosome 4 but away from the fragile site, as reference. To verify the SNCA probe, we performed FISH on fibroblasts with a heterozygous SNCA triplication and a control, and cingulate gyrus from fixed brain with a heterozygous SNCA duplication. Additional SNCA signals were detected where appropriate (Fig. 1B) . Multiple copies were sometimes hard to distinguish, appearing as larger apparently compound or elongated signals (Fig. 1B , arrowheads).
FISH shows low level gains of SNCA in nigra, more commonly in Parkinson's disease dopaminergic neurons than controls
We obtained successful hybridization, with no significant background, in 40 Parkinson's disease, 25 control, and five MSA nigras. The age of death, and onset and duration of disease are shown in Supplementary Fig. 4 and Supplementary Table 1 . We counted on average 142.1 neuromelanin-positive and 305.6 neuromelanin-negative cells per slide ( Supplementary Fig. 5 ). We observed a low proportion of nuclei with clear unique SNCA gains, with two copies of the reference, in both cell types, in many disease and control nigras, with very rare cells showing more than three SNCA copies ( Fig. 2 and Supplementary Table 1 ).
Comparing the proportions of brains with any evidence of gains, in each cell type and overall, between Parkinson's disease and controls, showed that Parkinson's disease nigras were far more likely to be positive for neuromelanin-positive cells (P = 0.0036), and overall (P = 0.0052), but this did not reach significance for neuromelanin-negative cells alone (P = 0.1144) ( Table 1) . We next compared the percentage of nuclei with SNCA gains in each nigra and cell type. Although the proportion of nuclei with gains was small (mean 0.78% in Parkinson's neuromelanin-positive cells), there was a significant difference across all groups (P = 0.032) (Fig. 3) . Pairwise comparisons between Parkinson's disease and control for each cell type showed a significantly higher proportion in Parkinson's disease for neuromelanin-positive (corrected P = 0.017), but not neuromelanin-negative cells (P = 0.202). We reviewed the histology report of the control with the highest gains in dopaminergic neurons (Subject C4; 1.87%), and noted incidental -synuclein pathology, with rare Lewy neurites in the substantia nigra, but no Lewy bodies. The few cells with more than three SNCA copies had four, except for one which had five. There were more in neuromelanin-positive than neuromelanin-negative cells overall, but this was not significant (7/9209 and 5/20 172, respectively, P = 0.088).
Within neuromelanin-positive cells, slightly more were in Parkinson's disease cases than controls, but this was not also significant (5/5677 and 2/3532 respectively, P = 0.715).
More complex patterns than straightforward gains are occasionally seen
We also noted very rare nuclei with other patterns (Supplementary Table 3 and Supplementary Fig. 6 ). Loss of one or both probes, seen in 0.53% and 0.12% of all neuromelanin-positive and neuromelanin-negative cells, respectively (P 5 0.001), could represent a real loss, or a sectioning artefact. Apparent gains of both SNCA and reference, seen in 0.14% and 0.16% of all neuromelaninpositive and neuromelanin-negative cells, respectively (P = 0.017), could be gains of the entire chromosome 4, or at least its long arm, or could be due to overlapping nuclei. Three of these cells, all in Parkinson's disease, had more than five SNCA copies, with the highest number being eight (one neuromelanin-positive; Supplementary  Fig. 6A ). There were also occasional cells with other patterns, e.g. three SNCA/one reference. It is hard to attribute this to sectioning, and the reverse pattern was never seen. Of 11 cells with this pattern (including three neuromelaninpositive), 10 were in disease (nine Parkinson's disease, one MSA), although not significantly more common in Parkinson's compared to control (P = 0.135). Three of these were from the same Parkinson's disease nigra (Case PD35; one neuromelanin-positive; Supplementary Fig. 6C ).
To ensure that we were not biasing our results by excluding cells with losses, or gains of both SNCA and reference, we also performed the following supplementary analyses. We calculated the mean SNCA copy number in cells with two or more copies of the reference (i.e. including nuclei with possible chromosomal gains, but excluding any which might have been partially sectioned). We also analysed the ratio of the total number of SNCA and reference signals, across all cells, including any with losses, as sectioning artefacts should have an equal chance of affecting SNCA or the reference locus. The results were essentially the same ( Supplementary Fig. 7 ), eliminating these rare nuclei as the cause of the differences observed.
The level of SNCA gains in dopaminergic neurons is negatively correlated with Parkinson's disease onset age If somatic mutations contribute to Parkinson's disease, their level may be higher in earlier onset (Frank, 2010; Proukakis et al., 2013) . Spearman correlation analysis of percentage of neuromelanin-positive cells with SNCA gain in Parkinson's disease showed a significant negative correlation with onset age (r = À 0.391, P = 0.013), but not disease duration, or age of death (Table 2 ). There was no significant correlation in neuromelanin-negative cells. We also found no correlation with age of death in controls (r = 0.002, P = 0.995). The only two Parkinson's disease cases with no gains in either cell type had the latest onset (Case PD34; 72 years) and the third-longest disease duration (Case PD40; 30 years). The only individual with onset under 50 who had no SNCA gains in neuromelaninpositive cells was the PARK2 missense variant carrier (Case PD3), with a 31-year disease duration. To investigate PARK2 further, we performed array-CGH on nigral DNA, which had not been done before in this case; this revealed one, and possibly two, PARK2 intronic deletions ( Supplementary Fig. 8 ).
Parkinson's cases with tremor at onset are less likely to have gains
We compared clinical features of cases with and without gains in neuromelanin-positive cells (Supplementary Tables  1 and 4 ). All cases presenting without tremor or asymmetry had gains, while asymmetric cases, which mostly also had tremor, sometimes did not. This difference was significant for tremor (P = 0.035) but not for asymmetry (P = 0.156). Hallucinations were reported in the majority of both groups (P = 0.447). The only cases with no gains in either cell type (Cases PD34 and PD40) had asymmetry and tremor, and no hallucinations.
Nigra from two multiple system atrophy brains shows the highest gains
We studied five MSA nigras, all with nigral neuronal synuclein pathology (nigrostriatal or mixed pattern), but did not include them in the statistical analysis because of their small number. We noted gains in neuromelanin-negative cells in all, and in four also in neuromelanin-positive. Indeed, the highest percentage of cells with SNCA gains were neuromelanin-positive in two MSA cases, studied in different experiments (Cases MSA1-2.76 and MSA2-2.48) (Fig. 4A, B Table 5 ).
Chromosome 4 paint indicates gains are on chromosome 4
We hypothesized that SNCA gains were likely to be in tandem, on the same chromosome, rather than translocations. We stained a nigra section from Case MSA1 with SNCA and chromosome paint (unblinded). We confirmed the rate of SNCA gains by extensive counting (neuromelanin-positive: 6/196, 3.06%; neuromelanin-negative: 28/ 3431, 0.82%). We recorded whether SNCA signals appeared to co-localize with chromosome 4. In normal cells, 97.5% of SNCA signals did (Fig. 4C) 
FISH with new probes and dye-swap confirms results
To ensure that the SNCA excess signals were not probe artefacts, we obtained a custom-designed green SNCA probe, and verified it on SNCA triplication fibroblasts ( Supplementary Fig. 9 ). We used two different red reference probes, one also targeting a gene on chromosome 4 (PDGFRA), 1 Mb away from the FIPL1 reference, and one on chromosome 7 (IZKF1) (Fig. 1A) . We performed three separate experiments using the green SNCA probe and the new references, on a total of seven nigra slides. Two experiments included slides hybridized with the original SNCA red/reference green probes, blinded for the probe type/colour. We found that the pattern was now essentially reversed, with green gains, and almost no red gains ( Fig. 5A ; details in Supplementary Table 6 ). Case MSA1 (analysed blinded to the probes) showed SNCA gains again. Nigra from Case MSA4, which had not been analysed before, showed remarkably similar gains when tested with green and red SNCA in a fully blinded experiment: in neuromelanin-positive cells, 0.66% with red SNCA, 0.64% with green; in neuromelanin-negative cells, 1.25% with red SNCA, 0.96% with green (Fig. 5B) . Finally, the total number of signals with the green SNCA probe now showed a clear excess of the green probe (ratio 1.0045 in neuromelanin-positive, and 1.0018 in neuromelanin-negative cells).
Reference probes show minimal or no gains
To ensure that gains were not simply a common feature of all probes, we calculated the proportion of cells of each type showing unique reference gains, which was 40.1% in neuromelanin-positive cells for all three probes used (Supplementary Table 8 ). The green FIPL1 reference probe had gains in 0.10% of neuromelanin-positive cells and 0.046% of neuromelanin-negative. The two red reference probes showed no gains in neuromelanin-positive cells; in neuromelanin-negative cells, PDGFRA showed no gains, and IKZF1 had gains in 0.23%.
Gains may also occur outside nigra
In Case MSA1, we also found gains in the putamen (5/476 cells; 1.05%), but not in frontal cortex (230 cells) or occipital cortex (408 cells) ( Supplementary Fig. 10A ). In the cerebellum, only 1 of 428 cells had a unique SNCA gain, although differentiating nuclei was difficult due to the tightly-packed granule cells. We also studied the frontal cortex from four Parkinson's disease brains in unblinded experiments, using NeuN immunohistochemistry to identify neurons (Supplementary Table 1 ). We observed three neurons with SNCA gains after counting $150 in each (0.49%; Supplementary Fig. 10B ), with no apparent glial gains.
Discussion
We investigated somatic SNCA gains in sporadic synucleinopathies by three different methods. To analyse DNA extracted from tissue homogenates, predominantly substantia nigra, we used digital droplet PCR and customized array comparative genomic hybridization. We excluded high-level SNCA copy number variant mosaicism ($20-30% of cells having an extra copy). These results could be consistent with a low level of somatic gains, or their presence only in certain cell types. We thus next investigated SNCA copy number in individual brain cells by FISH, focusing on the substantia nigra, where neuromelanin staining allows identification of dopaminergic neurons (Kordower et al., 2013; Nichterwitz et al., 2016) . We demonstrated low level gains of SNCA, commoner in nigral dopaminergic neurons of Parkinson's disease than controls, negatively correlated with onset age, validated by probe dye-swapping, with the highest levels in two MSA cases. As FISH may underestimate copy number by not resolving nearby gains (Bushman et al., 2015) , which we indeed noticed in the brain and fibroblast samples with known inherited copy number variants ( Fig. 2 and Supplementary Fig. 9 ), we may have underestimated gains. Indeed, we noted several cells where larger SNCA signals might have been due to this ( Figs 2C and 5B), but were conservative in our calls, requiring the presence of a spatially distinct signal on the microscope, and not calling additional copies based on signal size. We also noted occasional cells with more than three SNCA copies, and cells with increased numbers of SNCA and reference signals, which may have had up to eight SNCA copies, which would further increase the -synuclein load. The gains in Parkinson's disease nigral dopaminergic neurons showed significant negative correlation with onset age, as expected if somatic mutations have a role in disease SNCA red and green, on Case MSA4 nigra, never studied before. Experiment blinded to probes, diagnosis, and the fact these slides were from the same nigra. Neuromelanin-positive and neuromelanin-negative cells with SNCA gains revealed by both probes are shown. The arrow points to an unusually large SNCA signal, in a nucleus with at least one extra copy.
development (Frank, 2010) . Review of clinical data revealed an intriguing association of lack of tremor at presentation with presence of gains, suggesting that cases with tremor at onset may be less likely to have SNCA mosaicism. We are, by definition, only able to assess the cells that are still alive at the time of the individual's death, and cannot determine any possible gains in cells that preferentially died earlier. Neuromelanin staining may help detect more surviving dopaminergic neurons, as loss of tyrosine hydroxylase may occur before loss of melanized neurons (Kordower et al., 2013) . Even so, and despite trying to analyse cases with relatively short disease duration, it should be noted that half the dopaminergic neurons may be lost before a diagnosis is made, with an estimated 33-80% melanized neurons lost in the first decade (Kordower et al., 2013) , and our cases were all advanced pathologically (mostly Braak stage 6). The true burden of somatic SNCA gains in early stage of Parkinson's disease, or before onset, could therefore be much higher. We did not find significant pathological correlations with the presence or level of mosaicism, but our study was not designed for this, and more cases, particularly early stage, would be needed. We note that the highest levels of neuronal gains were in two MSA cases, and all five studied had gains in at least neuromelanin-negative cells. We did select MSA with clear neuronal nigral synuclein pathology, and cannot draw firm conclusions based on these few cases, but this clearly merits further study.
Notably, the only two Parkinson's disease cases without gains in either cell type had either a long duration (30 years) or late onset (age 72), suggesting that our selection of short duration and early onset was appropriate. Gains in dopaminergic neurons were absent in only 1 of 10 individuals with onset under 50, who also carried a PARK2 heterozygous missense variant, and at least one PARK2 intronic deletion (Supplementary Fig. 8 ). The lack of SNCA gains could be due to neurons carrying them being lost because of the very long disease duration (31 years, the joint longest). We wonder whether parkin (PARK2) dysfunction might have exacerbated this, or conversely whether SNCA gains are not present in cases with PARK2 mutations. As the pathology of this case was typical Parkinson's disease, however, and the significance of a single PARK2 coding variant and intronic PARK2 copy number variants remains unclear (Wang et al., 2013) , this may be a coincidence. PARK2 is also in a fragile site, and somatic deletions have been reported in glioblastoma (Veeriah et al., 2010) , but our array-CGH did not reveal other deletions.
We have been careful to base our analysis on cells that had two copies of the reference, and at least two of SNCA, to minimize any sectioning artefacts. The very low proportion of cells with losses (Supplementary Table 4) suggests that we did not often have partial nuclei. When we analysed data in different ways, also including cells with gains of both probes, or any losses, our key finding of gains in dopaminergic neurons being more common in Parkinson's disease cases compared to controls was still apparent (Supplementary Fig. 7 ). Although sectioning artefacts are possible, gains of both SNCA and reference could indicate a somatic whole chromosome gain, which would also increase the -synuclein load. Mosaic aneuploidy has been consistently reported in normal neurons in other brain regions, albeit at varying levels (Rehen et al., 2005; Iourov et al., 2009; Knouse et al., 2014) . Evidence is increasing for DNA replication in specific neuronal populations, in development or in neurodegeneration (Frade et al., 2015) , and polyploidy has been reported in Parkinson's disease nigral neurons (Hö glinger et al., 2007) . With regard to the few cells with gains of SNCA and loss of reference, possibly commoner in disease, the possibility of a somatic complex chromosomal rearrangement, as reported in mouse olfactory neurons (Hazen et al., 2016) , is a plausible but unproven explanation.
We only found minimal evidence of gains with three different reference probes. The main chromosome 4 reference probe, targeting FIPL1, had gains in 0.1% and 50.05% in neuromelanin-positive and neuromelanin-negative cells, respectively. These may represent true gains, or the false positive rate of our technique. No gains were seen with the other chromosome 4 probe. The relative lack of gains with the chromosome 4 probes used as reference is consistent with gains restricted to the fragile site around SNCA. The third reference probe, targeting a chromosome 7 locus, had gains only in 0.23% of neuromelanin-negative cells. This probe detects a locus that can be deleted in haematopoietic malignancies (Schwab et al., 2013) , although we are not aware of any somatic gains.
The somewhat surprising result of low level gains even in some controls may indicate genomic instability of SNCA in at least nigral dopaminergic neurons or their precursors, consistent with its presence in a fragile site (Rozier et al., 2004) . Interestingly, the control with the highest gains in dopaminergic neurons had rare Lewy neurites in the substantia nigra. It is impossible to know if she had lived past the age of 82 whether she would have developed the picture of incidental Lewy body disease, or even clinical Parkinson's disease. This highlights the difficulty in selecting controls in an age-related condition, which could have been even more problematic if we had selected younger ones. We should note that this is not the first report of somatic SNCA gains in normal human neurons, as a gain including SNCA was present in a frontal neuron from a young control (Subject FCTX225 in McConnell et al., 2013) .
Our study was mostly limited to one section from each nigra, and cells were selected based on neuromelanin positivity, rather than their precise anatomical location. Further work should seek to assess topographically defined nigral neuronal populations, differentiating between the ventrolateral and dorsomedial regions, correlate gains with SNCA/-synuclein mRNA and protein levels, and immunologically characterize neuromelanin-negative cells with gains. We have not performed a definitive assessment of other brain regions, or peripheral neuroectodermal structures, where pathology is often found (Beach et al., 2010) . Limited analysis of NeuN-labelled frontal neurons, and one MSA putamen and cerebellum, suggested some gains. We did not detect any significant pathological correlates of gains, and the lower prevalence of gains in cases with tremor has to be viewed as preliminary. More widespread regional analysis, and detailed correlation with clinical and pathological features, would be of great interest.
Further molecular characterization of SNCA gains, and detection of low-level copy number variants in other relevant genes like PARK2, may require single cell whole genome sequencing, which is advancing rapidly (Gawad et al., 2016) . Large copy number variants can be detected, although uneven amplification, which could lead to false positives, can only be minimized with novel protocols (Chen et al., 2017; Zahn et al., 2017) , untested on neurons. There are no sequencing data on nuclear DNA from single nigral neurons reported to our knowledge. One related finding, however, is the evidence for DNA content variation in neurons. Frontal neurons have increased DNA content compared to cerebellar and to lymphocytes (Westra et al., 2010) . This is particularly prominent in Alzheimer neurons, with some of the increase due to extra copies of APP, although the majority of the additional DNA remained unexplained (Bushman et al., 2015) . DNA content of nigral neurons was increased in Lewy body diseases compared to control and to other regions, without the source of extra DNA being known (Yang et al., 2015) , but not in MSA (Yang et al., 2017) .
SNCA gains may arise in very early development, where rapid expansion of neuronal precursors takes place, DNA replication stress may predispose to copy number variants in fragile sites, such as the ones where SNCA and PARK2 reside, and DNA breaks occur. The amount of -synuclein, an important presynaptic protein, influences the development of a subset of nigral dopaminergic neurons (GarciaReitboeck et al., 2013) , so developing neurons with losses might be at a selective disadvantage, although we cannot predict the effect of gains. Gains may additionally, or alternatively, arise in post-mitotic neurons, for example by aberrant cell cycle re-entry as claimed in Alzheimer's disease (Yang et al., 2001) , with mitotic activation also reported in Parkinson's nigral neurons (Hö glinger et al., 2007) . In this case, they could be a result of, rather than contributor to, the disease. Another question is whether SNCA gains in controls might make individual neurons more vulnerable to ageing, as reported for hyperploidy in Alzheimer's disease (Arendt et al., 2010) , and for increased DNA content in ageing (Fischer et al., 2012) . Although we used mostly old controls, we found no correlation of gains with age of death.
In conclusion, we present evidence of low level somatic SNCA gains in brain, predominantly in nigral dopaminergic neurons, where they are more common in Parkinson's disease than in controls, negatively correlated with onset age, and possibly most common in some MSA cases. Our findings are analogous to Alzheimer's disease, where rare inherited APP gains are pathogenic, and somatic gains commoner in disease frontal neurons (Bushman et al., 2015) . Gains may arise in early embryonic development, in which case they might be detectable in peripheral neural crest-derived structures (Proukakis et al., 2013) . They could have a role in disease initiation, as 'seeds' from where pathology propagates, or progression, by increasing sensitivity of neurons to intrinsic or extrinsic harmful processes. They may also result from aberrant DNA synthesis in neurodegeneration. Progress in single cell sequencing will help confirm the level of SNCA gains, define their breakpoints, and shed light on the timing and mechanism of their origin.
